Correlation of Quantitative EEG and Tumor Necrosis Factor Alpha Induced Protein-8 Like-2 in Cognitive Evaluation of Patients with Parkinson Disease
/ 0
- Details
- Category: Vol. 92, June 2024
- Hits: 54
Correlation of Quantitative EEG and Tumor Necrosis Factor Alpha Induced Protein-8 Like-2 in Cognitive Evaluation of Patients with Parkinson Disease, ASMAA F. IBRAHIM, HOSSAM H. ABOUBAKR, MOHAMMED M. MASOUD, RASHA H. SOLIMAN and MOSTAFA M. ELKHOLY
Background: Cognitive deterioration is common and dev-astating in patients with Parkinson disease (PD). Aim of Study: To explore the correlation between quantita-tive spectral Electroencephalography (EEG) measures and se-rum levels of Tumor Necrosis Factor Alpha Induced Protein-8 Like-2 (TIPE2) in cognitive assessment of PD patients. Patients and Methods: This case control study enrolled 80 participants (40 PD patients and 40 matched healthy controls). Patients were subjected to clinical and neuropsychological as-sessment using unified Parkinson’s disease Rating Scale (UP-DRS), Modified Hoehn and Yahr staging scale (HY), and Mon-treal Cognitive Assessment Scale (MOCA). Quantitative EEG (QEEG) assessment of all study participants included spectral relative power and peak frequency of delta, theta, alpha and beta bands over bilateral frontal, temporal and occipital regions TIPE2 serum level was measured in all participants. Results: PD patients had statistically significant higher TIPE2 serum levels and relative power of all frequency bands especially over the right temporal region. TIPE2 levels cor-related with UPDRS and HY clinical severity scales. Frontal and temporal alpha/beta relative powers correlated with total MoCA score and its individual cognitive domains while TIPE2 correlated with visuospatial/executive function. TIPE2 levels correlated with spectral peak frequency of delta, theta and alpha bands over frontal and temporal regions. Conclusions: Serum TIPE2 levels and quantitative spec-tral EEG measures have a potential role supporting clinical and neuropsychological assessment of patients with PD.